A Phase II Study (GOG 153) of Recurrent and Advanced Endometrial Carcinoma Treated with Alternating Courses of Megestrol Acetate and Tamoxifen Citrate

Theodore Robnett, MD
OncoLink Assistant Editor
Last Modified: May 20, 2000

Presenter: James V. Fiorica
Affiliation: H. Lee Moffitt Cancer Center, others


Progestins are commonly used in the treatment of endometrial cancer, but downregOLation of progesterone receptors may shorten response duration. Tamoxifen binding may recruit receptors and thus increase response duration. This phase II trial tests this hypothesis by alternating these agents.

Materials and Methods:

  1. Treatment consisted of Megestrol Acetate (MA), 160mg x 3 weeks alternating with Tamoxifen Citrate (T), 40mg x 3 weeks in divided doses.
  2. Eligibility: Patients with recurrent or advanced endometrial cancer. Failure to respond to, or considered incurable with local therapy with no prior hormonal or cytotoxic therapy. No concurrent malignancy or recent radiation therapy was allowed.
  3. Primary endpoints were response rate and toxicity.
  4. Standard GOG toxicity and response criteria were used.


  1. 61 patients were entered, 56 were evaluable. 59% had prior radiation therapy. Distribution of tumor grades was approximately even.
  2. There were 15 responders (90% CI 17%-38%): 12 had a complete response, and 3 had a partial response. Response rates for Grade I, II, and III disease were 38%, 24%, and 22% respectively.
  3. Duration of response exceeded 20 months in 8 of the 15 responders.
  4. Women 60 and younger had a better response rate (44%) than women older than 60 (25%).
  5. 4/56 patients had grade III toxicity: 2 pOLmonary embolism, 1 neurologic, 1 GU. The most common toxicity was grade I weight gain.

Authors' Conclusions

The discussion session addressed the issues of differences in the distribution of age and tumor grade. In a small study such as this, carefOL attention must be directed toward making conclusions based on different patient popOLations.

Clinical/Scientific Implications:

MA and T are active in endometrial cancer and may offer a prolonged response interval.


Catherine and Finn
by OncoLink Editorial Team
December 01, 2015

Related News

ASCO: Extending Tamoxifen to Ten Years is Beneficial

Jun 5, 2013

Reductions in breast cancer recurrence, death for women taking tamoxifen for 10 versus five years

Short-, Long-Course Therapy Comparable in T3 Rectal Cancer

Sep 27, 2012

No significant differences in rates of local, distant recurrence; overall survival; or late toxicity

Study finds that well below 1 percent of women were taking tamoxifen in 2000 and 2005

Feb 9, 2010

Study finds that well below 1 percent of women were taking tamoxifen in 2000 and 2005